Comparison of laboratorial tests for the diagnosis of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) in HIV-1 infected patients
PDF (Português (Brasil))

Keywords

HTLV-1/2
diagnosis
serology
PCR
HIV-1/HTLV-coinfection
algorithm tests

How to Cite

1.
Campos KR, Gonçalves MG, Fukasawa LO, Costa NA, Barreto-Damião CH, Magri MC, Alencar WK, Caterino-De-Araujo A. Comparison of laboratorial tests for the diagnosis of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) in HIV-1 infected patients. Rev Inst Adolfo Lutz [Internet]. 2015 Oct. 5 [cited 2024 Nov. 23];74(1):57-65. Available from: https://periodicos.saude.sp.gov.br/RIAL/article/view/33386

Abstract

The present study aimed at investigating the best algorithm definition to be employed for diagnosing the human T lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) in HIV-1 infected/Aids patients. Blood samples of 1,608 HIV-1 infected patients from the AIDS Reference Center (CRT DST/AIDS-SP) were tested for the presence of HTLV-1/2 antibodies using two screening assays (EIA Murex HTLV-I+II, and Gold ELISA HTLV-I/II), and confirmed by two Blots [HTLV Blot 2.4 (Western Blot –WB) and INNO-LIA HTLV I/II (Line ImmunoAssay - LIA)], and one molecular assay (pol real-time PCR). The screening tests detected 51(Murex) and 49 (Gold ELISA) reagents sera. WB , confirmed 23 HTLV-1, 12 HTLV-2, six HTLV, and nine showed HTLV indeterminate profiles. LIA confirmed 24 HTLV-1, 20 HTLV-2, and six HTLV. PCR detected 18 HTLV-1- and 12 HTLV-2-infected blood samples. By using any confirmatory assay, 50 patients confirmed HTLV infection: 25 HTLV-1 (1.55 %), 21 HTLV-2 (1.31 %) and four HTLV (0.25 %). The sensitivity of LIA, WB and PCR assays were 96 %, 76 % and 60 %, respectively. By considering the assays cost as the sole variable, the best testing algorithm for diagnosing HIV-1/HTLV-coinfection in HIV-1 infected patient was the use of PCR followed by LIA technique.
https://doi.org/10.53393/rial.2015.v74.33386
PDF (Português (Brasil))

References

1. Gallo RC, Sliski A, Wong-Staal F. Origin of human T-cell leukaemia-lymphoma virus. Lancet. 1983; 322(8356): 962-3. doi:10.1016/S0140-6736(83)90471-3

2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982; 218(4572): 571-3. doi: 10.1126/science.6981847.

3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovírus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980; 77(12): 7415-9.

4. Brites C, Sampaio J, Oliveira A. HIV-1/Human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev. 2009; 11(1): 8-16. doi: 10.1086/595013

5. Moriuchi H, Moriuchi M, Fauci A. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med. 1998; 187(10): 1689-97.

6. Moriuchi H, Moriuchi M. In vitro induction of HIV-1 replication in resting CD4+ T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I. Virology. 2000; 278(2): 514-9. doi:10.1006/viro.2000.0684

7. Bagheri F, Patel K, Samourjian E, Pathak N, Shamalov V, Gintautas J et al. Further evidence that HTLV protects against HIV-1 progression. Infect Med J. 2008; 1-5.

8. Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004; 6(3): 144-54.

9. Caterino-de-Araujo A, Santos-Fortuna E, Meleiro MCZ, Suleiman J, Calabro ML, Favero A et al. Sensitivity of two ELISA tests in relation to Western blot in detecting HTLV-I and HTLV-II infection among HIV-1-infected patients from São Paulo, Brazil. Diagn Microbiol Infect Dis. 1998; 30(3): 173-82. doi:10.1016/S0732-8893(97)00236-8

10. Caterino-de-Araujo A. Best screening assays for the diagnosis of human T-cell lymphotropic virus types 1 and 2 in South America. J Virol Methods. 2008; 156(1-2): 150-1. doi: 10.1016/j.jviromet.2008.10.003.

11. Caterino-de-Araujo A. Diagnóstico de infecção por vírus linfotrópicos de células T humanas dos tipos 1 (HTLV-1) e -2 (HTLV-2) em população de risco: passado, presente e futuro. Rev Inst Adolfo Lutz. 2009; 68(2): 182-6.

12. Costa EAS. Introdução da reação em cadeia da polimerase em tempo real no algoritmo de testes laboratoriais para o diagnóstico de infecção por HTLV-1 e HTLV-2 [dissertação]. São Paulo (SP): Coordenadoria de Controle de Doenças da Secretaria de Estado da Saúde, 2010. 101pp.

13. Jacob F, Magri MC, Costa EAS, Santos-Fortuna E, Caterino-de Araujo A. Comparison of signal-to-cutoff values in first, second, and third generation enzyme immunoassays for the diagnosis of HTLV-1/2 infection in “at-risk” individuals from São Paulo, Brazil. J Virol Methods. 2009; 159(2): 288-90. doi: 10.1016/j.jviromet.2009.03.024.

14. Jacob F, Santos-Fortuna E, Azevedo RS, Caterino-de-Araujo A. Performances of HTLV serological tests in diagnosing HTLV infection in high-risk population of São Paulo, Brazil. Rev Inst Med Trop S Paulo. 2007; 49(6): 361-4. http://dx.doi.org/10.1590/S0036-46652007000600005

15. Jacob F, Santos-Fortuna E, Azevedo RS, Caterino-de-Araujo A. Serological patterns and temporal trends of HTLV-1/2 infection in high-risk populations attending Public Health Units in São Paulo, Brazil. J Clin Virol. 2008; 42(2): 149-55. doi: 10.1016/j.jcv.2008.01.017.

16. Jacob F, Santos-Fortuna E, Caterino-de-Araujo A. Algoritmo de testes sorológicos de triagem para infecção por HTLV-1/2 usado no Instituto Adolfo Lutz de São Paulo. BEPA. 2008; 5:12-8.

17. Costa JMP, Costa EAS, Segurado AAC. Infecção por HTLV-I e HTLV-II. In: Ferreira AW, Moraes SL. Diagnóstico Laboratorial das Principais Doenças Infecciosas e Autoimunes. 3 ed. Rio de Janeiro: Guanabara Koogan; 2013. p.120-34.

18. Caterino-de-Araujo A. Diagnóstico sorológico e molecular do HTLV-1 e HTLV-2. Experiência de um Laboratório de Saúde Pública do Brasil. Rev Cienc Med PE. 2011; 7(2): 123-7.

19. Ishaki R, Vallinoto ACR, Azevedo VN, Vicente ACP, Hall WW, Ishaki MOG. Molecular evidence for infection by HTLV-2 among individuals with negative sorological screening tests for HTLV antibodies. Epidemiol Infect. 2007; 135(4): 604-9. doi: 10.1017/S0950268806006984.

20. Berini CA, Pascuccio MS, Bautista CT, Gendler SA, Eirin ME, Rodriguez C et al. Comparison of four commercial screening assays for the diagnosis of human T-cell Lymphotropic vírus types 1 and 2. J. Virol. Methods. 2008; 147(2): 322-7. doi:10.1016/j.jviromet.2007.09.012.

21. Bassani S, Toro C, Jiménez V, Rodés B, Soriano V. Can the level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis? Clin Vaccine Immunol. 2006; 13(1): 160-1. doi: 10.1128/CVI.13.1.160-161.2006.

22. Morimoto HK, Morimoto AA, Reiche EMV, Ueda LT, Matsuo T, Reice FV et al. Difficulties in the diagnosis of HTLV-2 infection in HIV-1/AIDS patients from Brazil: Comparative performances of serologic and molecular assays, and detection of HTLV-2b subtype. Rev Inst Med Trop S Paulo. 2007; 49(4): 225-30. http://dx.doi.org/10.1590/S0036-46652007000400006

23. Costa EAS, Magri MC, Caterino-Araujo A. The best algorithm to confirm the diagnosis of HTLV-1 and HTLV-2 in at-risk individuals from São Paulo, Brazil. J Virol Methods. 2011; 173(2): 280-6. doi: 10.1016/j.jviromet.2011.02.018

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2015 Instituto Adolfo Lutz Journal

Downloads

Download data is not yet available.